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ABSTRACT A novel selective agar (RGM medium) has been advocated for the isola-
tion of rapidly growing mycobacteria from the sputa of cystic fibrosis (CF) patients.
The aim of this study was to compare RGM medium to Burkholderia cepacia selective
agar (BCSA) and a standard acid-fast bacillus (AFB) culture method for the isolation
of nontuberculous mycobacteria (NTM) from patients with CF. The applicability of
matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) for the identification of NTM isolated on RGM medium was also assessed.
Respiratory samples (n  869) were collected from 487 CF patients and inoculated
directly onto RGM medium and BCSA. Cultures were incubated at 30°C and exam-
ined for up to 28 days. A subset of 212 samples (from 172 patients) was also cul-
tured by using a mycobacterial growth indicator tube (MGIT) and on Lowenstein-
Jensen medium following dual decontamination. By using a combination of all
methods, 98 mycobacteria were isolated from 869 samples (11.3%). The sensitivity of
RGM medium (96.9%) was significantly higher than that of BCSA (35.7%) for the iso-
lation of mycobacteria (P  0.0001). The sensitivity of RGM medium was also supe-
rior to that of standard AFB culture for the isolation of mycobacteria (92.2% versus
47.1%; P  0.0001). MALDI-TOF MS was effective for the identification of mycobacte-
ria in RGM medium. RGM medium offers a simple and highly effective tool for the
isolation of NTM from patients with CF. Extended incubation of RGM medium for 28
days facilitates the isolation of slow-growing species, including members of the My-
cobacterium avium complex (MAVC).
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Nontuberculous mycobacteria (NTM) are recognized as significant respiratorypathogens in patients with cystic fibrosis (CF) (1). In the largest studies of CF
patients, the prevalence of NTM in sputum has been estimated to be 6 to 13% (2) and
is thought to be increasing (3–6). For the detection of NTM in sputum samples,
international guidelines recommend the use of an automated liquid culture method
(such as the mycobacterial growth indicator tube [MGIT]) and note that additional
culture on solid media, such as Lowenstein-Jensen (LJ) medium, may increase recovery
(1). These culture methods rely upon the initial decontamination of the sputum sample
by using chemical treatments such as N-acetyl-L-cysteine (NALC) (0.5%) plus sodium
hydroxide (NaOH) (2%), and decontamination is intended to eliminate nonmycobac-
terial species that might otherwise compromise the isolation of NTM. Such methods are
problematic, as contaminated cultures may frequently occur, despite decontamination,
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or the number of viable mycobacteria may be reduced by the decontamination process
(7–9).
Esther et al. demonstrated previously that extending the incubation time on Burk-
holderia cepacia selective agar (BCSA) from 5 to 14 days afforded an increased rate of
recovery of NTM, and this has been used as an expedient method for the isolation of
NTM (10). However, overgrowth of cultures with fungi and Gram-negative bacteria
remains a problem, and this method has a lower sensitivity than that of standard
acid-fact bacillus (AFB) culture (AFBC) methods (10). RGM medium is a novel agar-based
medium that was specifically developed for the isolation of rapidly growing species of
mycobacteria such as members of the Mycobacterium abscessus complex (MABSC) (11).
In two European studies, RGM medium was shown to have a sensitivity superior to that
of BCSA for the isolation of rapidly growing mycobacteria from the sputum samples of
CF patients by using a 10-day incubation period for both media (11, 12). In a third
European study, the use of RGM medium with a 10-day incubation period was shown
to have a sensitivity equivalent to that of automated liquid culture using the MGIT (13).
The aim of this study was to assess the utility of RGM medium in a clinical laboratory
in the United States and to examine whether an extended incubation time from 10 to
28 days might enhance the isolation of slow-growing species of NTM such as members
of the Mycobacterium avium complex (MAVC). The compatibility of matrix-assisted laser
desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) was also
assessed with colonies of known species of mycobacteria cultured on RGM medium
and BCSA.
(Part of this work was presented at ASM Microbe 2016, Boston, MA, USA.)
RESULTS
Comparison between BCSA and RGM medium incubated for 28 days. A total of
869 respiratory samples from 487 CF patients were submitted for routine CF culture
and/or culture for mycobacteria during the study period. The age range of patients was
1 year to 71 years, with a median age of 14.9 years, and 53.6% of the patients were
female. The samples included 507 (58.4%) sputum/tracheal aspirates, 314 (36.1%) deep
pharyngeal (DP) swabs, and 48 (5.5%) bronchial washing (BW)/bronchoalveolar lavage
(BAL) fluid specimens.
A total of 98 isolates of NTM were recovered from the 869 patient samples (11.3%)
by using a combination of all methods. These 98 isolates were recovered from 69
distinct patients, giving a prevalence of 14.2% among this population of patients. The
overall sensitivities of RGM medium and BCSA were 96.9% and 35.7%, respectively (P
0.0001) (Table 1). TheM. abscessus complex accounted for the majority of mycobacterial
isolates by using both methods (prevalence of 5.5%). RGM medium had a significantly
higher sensitivity than that of BCSA for the recovery of MABSC organisms (100% versus
62.5%; P  0.001), M. chelonae (100% versus 12.5%; P  0.0005), and M. mucogenicum
(100% versus 62.5%; P  0.013). Of 35 mycobacteria isolated on BCSA, 32 isolates were
TABLE 1Mycobacteria from 869 respiratory samples of 487 patients with cystic fibrosis recovered on RGM medium and BCSA
Organism
Total no. of
mycobacteria
28-day BCSA 28-day RGM medium
P value
No. of mycobacteria
recovered Sensitivity (%)
No. of mycobacteria
recovered Sensitivity (%)
M. abscessus complex 48 30 62.5 48 100 0.0001
M. chelonae 16 2 12.5 16 100 0.0005
M. immunogenum 11 3 27.3 8 72.7 0.228
M. mucogenicum 8 0 0 8 100 0.013
M. avium complex 8 0 0 8 100 0.013
M. gordonae 4 0 0 4 100
M. arupense-M. nonchromogenicum 1 0 0 1 100
M. nebraskense 1 0 0 1 100
M. llatzerense 1 0 0 1 100
Total 98 35 35.7 95 96.9 0.0001
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detected on RGM medium, but 3 isolates of M. immunogenum were isolated only on
BCSA. Slow-growing mycobacteria were recovered only from RGM medium, including
MAVC organisms (n  8), M. gordonae (n  4), M. arupense-M. nonchromogenicum (n 
1), and M. nebraskense (n  1). Almost all (34 of 35) isolates on BCSA were recovered
within 14 days of incubation, a standard protocol for the screening of rapidly growing
mycobacteria in our laboratory. An improved recovery of NTM was observed for all
sample types. The proportions of positive DP swabs, sputum/tracheal aspirates, and
BW/BAL fluid specimens with NTM increased from 0.6%, 5.1%, and 14.6% on BCSA to
5.4%, 12.2%, and 25% on RGM medium, respectively. As a result of extending the
incubation time from 10 to 28 days, 35 additional isolates of NTM were recovered on
RGM medium, including both rapidly growing species, e.g., MABSC organisms (n  9),
and slow-growing species, e.g., MAVC organisms (n  6) (Fig. 1). Forty-eight NTM-
positive patients had 2 sequential samples collected. Of these patients, 14 (29.2%)
patients had 2 more positive cultures: 55% had MABSC organisms (11 of 20 patients),
10% had M. chelonae (1 of 10 patients), and 66.7% of MAVC organisms (2 of 3 patients).
The remaining 34 patients had NTM isolated only once, including MABSC organisms
(n  9), M. chelonae (n  9), M. immunogenum (n  6), M. mucogenicum (n  6), MAVC
organisms (n  1), M. arupense-M. nonchromogenicum (n  1), M. nebraskense (n  1),
and M. gordonae (n  1).
Nonmycobacterial species were recovered from 243 BCSA cultures (28.1%) and 95
RGM medium cultures (10.9%) (Table 2). Gram-negative bacilli (n 117) and fungi (n
121) accounted for the majority of nonmycobacteria isolated on BCSA. On RGM
medium, Gram-negative bacilli (n  74) were the leading group of organisms, whereas
fungi were mostly inhibited, except for 7 Candida species and 13 Trichosporon species.
Comparison between 28-day culture on RGM medium and 56-day culture for
mycobacteria using MGIT and LJ medium (AFBC). A subset of 212 samples, which
comprised 164 (77.4%) sputum/tracheal aspirates, 4 (1.9%) DP swabs, and 44 (20.7%)
BW/BAL fluid specimens, from 172 patients also had a simultaneous culture performed
for mycobacteria in addition to culture on RGM medium and BCSA.
A total of 51 mycobacteria were recovered by using a combination of the three
methods (24.1%). RGMmedium showed a higher rate of recovery of NTM than did AFBC
(92.2% versus 47.1%; P 0.0001) (Table 3). The proportions of positive sputum/tracheal
aspirates and BW/BAL fluid specimens with NTM increased from 12.8% and 4.5% upon
AFBC to 20.7% and 18.1% on RGM medium, respectively. RGM medium missed one
MABSC isolate and two MAVC isolates that were isolated by AFBC, while the use of
AFBC was unable to recover 9 MABSC, 1 MAVC, and 14 other NTM isolates that grew on
FIG 1 Cumulative time to detection of NTM recovered on RGM medium and BCSA from 869 respiratory
samples of 487 patients with cystic fibrosis.
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RGM medium. Fifteen samples had positive auramine-rhodamine stains. All smear-
positive samples yielded mycobacteria by using RGM medium, whereas 13 (86.7%) of
these samples yielded mycobacteria from AFBC. Only MABSC organisms and a mix of
M. gordonae and M. mucogenicum could be isolated from the two cultures by using
RGM medium. The rate of recovery of MABSC organisms was significantly higher by
using RGM medium than by using AFBC (sensitivity of 96.6% versus 62.1%; P  0.009).
MAVC organisms were isolated from 7 samples by using a combination of methods
(prevalence of 3.3%). The rates of recovery of MAVC organisms were comparable
between RGM medium (5 of 7 isolates recovered) and AFBC (6 of 7 isolates recovered).
The cumulative time to positivity is shown in Fig. 2, with time points being selected for
AFBC that allow a direct comparison of the two methods. All mycobacteria that were
isolated by AFBC were detected within 14 days of incubation, whereas only 36 (76.6%)
of 47 isolates were recovered within 14 days by using RGM medium. The extended
incubation time helped to detect 11 more NTM on RGM medium, including 2 MABSC
and 2 MAVC organisms.
Nonmycobacterial organisms were recovered from 28 samples (13.2%) on RGM
medium, including 24 Gram-negative bacilli and 4 fungi. There were 30 AFBCs (14.1%)
from which mycobacteria could not be recovered due to the overgrowth of other
TABLE 2 Nonmycobacterial organisms from 869 respiratory samples of 487 patients with
cystic fibrosis recovered on RGM medium and BCSA
Organism
No. of organisms recovered
28-day culture
on BCSA
28-day culture on
RGM medium Total
Burkholderia species 54 42 54
Achromobacter species 16 17 22
Pandoraea species 10 10 10
Pseudomonas aeruginosa 9 0 9
Stenotrophomonas maltophilia 6 0 6
Chryseobacterium species 6 0 6
Ralstonia species 6 0 6
Inquilinus species 4 4 4
Serratia marcescens 3 1 3
Providencia rettgeri 1 0 1
Morganella morganii 1 0 1
Staphylococcus aureus 4 0 4
Enterococcus faecalis 2 0 2
Streptomyces species 0 1 1
Mold 55 0 55
Candida species 55 7 56
Trichosporon species 11 13 14
Total 243 95 254
TABLE 3Mycobacteria from 212 respiratory samples of 172 patients with cystic fibrosis recovered on RGM medium, BCSA, and
conventional mycobacterial culture using MGIT and solid medium
Organism
Total no. of
mycobacteria
28-day culture on BCSA 56-day AFB culture
28-day culture on RGM
medium
P valuea
No. of
mycobacteria
recovered Sensitivity (%)
No. of
mycobacteria
recovered Sensitivity (%)
No. of
mycobacteria
recovered Sensitivity (%)
M. abscessus complex 29 7 24.1 18 62.1 28 96.6 0.009
M. chelonae 5 3 60.0 0 0 5 100
M. immunogenum 3 1 33.3 0 0 2 66.7
M. avium complex 7 0 0 6 85.7 5 71.4
M. mucogenicum 4 0 0 0 0 4 100
M. gordonae 3 0 0 0 0 3 100
Total 51 11 21.6 24 47.1 47 92.2 0.0001
aComparisons between 56-day AFBC and 28-day RGM medium culture.
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organisms in both the MGIT and LJ medium. An additional 52 LJ and 2 MGIT samples
were discarded due to overgrowth.
Performance of MALDI-TOF MS for identification of rapidly growing myco-
bacteria on BCSA and RGM medium. All 41 archived isolates grew on RGM
medium; however, 1 MABSC, 4 M. fortuitum complex, and 4 M. mucogenicum
isolates did not grow on BCSA at 30°C in air, even if the incubation time was
extended to 7 days. All NTM on both media could be correctly identified by
MALDI-TOF MS with bioMérieux RUO SARAMIS Knowledge Base database scores of
75.0%, except for 1 M. immunogenum isolate on BCSA. However, all isolates could
be identified by using the bioMérieux in vitro diagnostic (IVD) system with the
updated v3.0 Knowledge Base database. Subspecies-level identification was not
included in any of the databases used in this study.
DISCUSSION
Specific species of NTM such as MABSC organisms are considered significant CF
pathogens and are associated with poorer clinical outcomes (14). The isolation of NTM
from respiratory samples of CF patients is challenging because of bacterial and fungal
overgrowth in AFB cultures. RGM medium, a novel selective medium designed for the
isolation of MABSC organisms, has been shown to have promise for the isolation of
rapidly growing mycobacteria from the sputa of CF patients (11–13). We are the first
U.S. center to evaluate this medium with the largest number of samples to date.
Extending the incubation time of RGM medium from 10 to 28 days and comparison
between RGM medium and 8-week AFBC using an MGIT and LJ medium were intended
to give a preliminary assessment of the ability to detect slowly growing mycobacteria
on this medium.
RGM medium is superior to BCSA for the recovery of rapidly growing mycobacteria,
with a sensitivity for the detection of NTM on RGM medium of 96.9%, compared with
35.7% on BCSA (P  0.0001). A higher level of recovery was observed on RGM medium
for MABSC, M. chelonae, M. mucogenicum, and MAVC isolates. The increased sensitivity
is consistent with data from a previous study by Preece et al., who evaluated the
recovery of rapidly growing mycobacteria from 502 sputum samples using a 10-day
incubation of RGM medium and BCSA and reported sensitivities of 98% and 31%,
respectively (P  0.0001) (11). Extending the incubation time from 10 to 28 days had
a significant impact on the recovery of slow-growing mycobacteria but also on the
recovery of rapidly growing mycobacteria (Fig. 1). Of 98 NTM recovered by using a
FIG 2 Cumulative time to detection of NTM recovered from 212 respiratory samples of 172 patients with
cystic fibrosis using RGM medium and conventional mycobacterial culture (AFBC) with an MGIT and solid
medium.
RGM Medium for Recovery of NTM from CF Patients Journal of Clinical Microbiology
May 2017 Volume 55 Issue 5 jcm.asm.org 1473
combination of RGM medium and BCSA, only 60 isolates (61.2%) were recovered on
RGM medium within 10 days of incubation, compared with 94 isolates (96.9%) being
recovered on the same medium after 28 days of incubation (P  0.001). The ability of
RGM medium to recover slow-growing species such as members of the MAVC, an
important pathogen in CF, raises the possibility of using RGM medium incubated for 28
days as a screening culture for all NTM in CF patients. RGM medium is also more
selective than BCSA, as shown by fewer nonmycobacterial organisms detected (10.9%
versus 28.1%); however, the inhibitory effect may be lost over the prolonged incubation
time since 8 more isolates of Burkholderia species were recovered after 14 days of
incubation.
Eltringham et al. compared the sensitivity of RGM medium incubated for 10 days
with that of 6-week MGIT cultures (13). A total of 187 sputum samples were directly
inoculated onto RGM medium and were decontaminated by using 3% oxalic acid
before inoculation into an MGIT. The level of detection of mycobacteria on RGM
medium was equivalent to that with the MGIT (sensitivity of 82% versus 86%; P 
1.000). In the study presented here, there was also no statistical difference between
AFBC and culture on RGM medium if results for RGM medium were analyzed after 10
days of incubation (P  0.136). RGM medium had a higher sensitivity than that of
standard AFB culture using a combination of the MGIT and LJ medium (92.2% versus
47.1%; P  0.0001). The rate of recovery of MABSC organisms was significantly higher
on RGM medium, and the rate of recovery of MAVC organisms was equivalent to that
achieved by AFBC. In our laboratory, all specimens from CF patients undergo two-step
decontamination with NALC-NaOH followed by 2.5% oxalic acid prior to culture. This
harsh treatment may result in a reduced recovery of NTM on AFBC, especially with
specimens containing low numbers of NTM. Bange et al. showed previously that 3 NTM
from 406 specimens could not be isolated after two-step decontamination despite
being recovered after decontamination with NALC-NaOH (15). It was notable that
mycobacteria were recovered from two AFB smear-positive specimens on RGM me-
dium but were not recovered from samples subjected to dual decontamination by
using standard AFBC. RGM medium has potential benefits over AFBC because of its
enhanced sensitivity and high specificity coupled with its relative simplicity. The use of
RGM medium requires no decontamination and may reduce labor and material costs.
Another potential advantage of RGM medium is the possibility of recovering MAVC
organisms from a mixed culture. We isolated MAVC and MABSC organisms on RGM
medium from a culture from which only MABSC organisms could be recovered by AFBC
(Fig. 3). We also showed that NTM growing on RGMmedium could be reliably identified
FIG 3 Colonies of M. abscessus complex (black arrow) and M. avium complex (white arrow) organisms on
RGM medium after 14 days of incubation.
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by using MALDI-TOF MS. MALDI-TOF MS has been the method for the identification of
rapidly growing mycobacteria in our laboratory since 2014 after thorough validation.
However, further study to evaluate the performance of MALDI-TOF MS on RGMmedium
can be achieved by the selection of reference isolates that have been identified by a
method other than MALDI-TOF MS. An additional application of this medium may be
its use in the culture of specimens from patients with other chronic lung diseases, such
as chronic obstructive pulmonary disease, or from patients with non-CF bronchiectasis.
The single potential advantage of AFBC over culture on RGM medium would appear to
be its capacity to accommodate the isolation ofMycobacterium tuberculosis, a pathogen
that is rarely encountered in patients with CF. Although RGM medium is not yet
commercially available, its formulation was previously reported (12). The time of
stability of this medium was previously demonstrated to be at least 12 weeks when
stored at 4°C (11).
There are at least three shortcomings to this study. First, we do not have good
longitudinal data, which is inherent in a study that was of only a 5-month duration. We
found three NTM species, M. chelonae, M. immunogenum, and M. mucogenicum, that
have only recently been recovered in our CF population largely because of the use of
RGM medium. The clinical significance of these organisms is not understood and
requires careful longitudinal study, as has been done with both MAVC organisms and
M. abscessus, the other organisms found frequently in this study (16). Second, RGM
medium is responsible for increased “noise” in these culture results. M. gordonae, an
organism typically viewed as an environmental contaminant of mycobacterial cultures,
was found in several RGM medium cultures but not in either BCSA or standard AFB
cultures. Although RGM medium enhances recovery, it may also increase the likelihood
of noise as well as “signal,” especially if M. chelonae, M. immunogenum, and M.
mucogenicum isolates prove to be more likely to represent contamination or transient
colonization. Third, although our data suggest that RGM medium may be used for the
recovery of MAVC organisms from respiratory specimens, the number of isolates found
in this study is too low to draw firm conclusions about its applicability for the recovery
of slow-growing organisms, especially since they may grow better at 35 to 37°C than
at 30°C, the temperature used in the present study (17). Additional studies under
various incubation conditions are needed to answer this question. Additional technical
issues regarding extended incubation should also be addressed thoroughly, including
biosafety, stability of the culture medium, and the possibility of environmental con-
tamination.
RGM medium offers a higher rate of recovery of NTM and is more selective than
BCSA. The sensitivity for the recovery of NTM is also significantly higher than that
of conventional mycobacterial culture. An extended incubation time on RGM
medium of 28 days facilitates the isolation of both rapid-growing mycobacteria and
slow-growing species, including MAVC organisms. There is the potential to replace
mycobacterial culture of CF respiratory samples with the more simple and effective
RGM medium.
MATERIALS AND METHODS
Patient samples. Respiratory samples from adults and children with cystic fibrosis that were
submitted to the Clinical Microbiology-Immunology Laboratories, UNC Health Care, Chapel Hill, NC,
USA, for routine culture and culture for mycobacteria were prospectively collected from December
2015 to April 2016. Specimen types included DP swabs, sputum/tracheal aspirates, and BW and BAL
fluids. This study was approved by the UNC Institutional Review Board (IRB) (approval number
15-2890).
Specimen processing and culture method for BCSA and RGM medium. RGM medium was
prepared at the Microbiology Department, Freeman Hospital, Newcastle upon Tyne, UK, as previously
described and transported to UNC Health Care, Chapel Hill, NC (12). RGM medium is based on
Middlebrook 7H9 medium supplemented with oleic acid-albumin-dextrose-catalase (OADC) and a
mixture of four antimicrobials: fosfomycin, colistin, amphotericin B, and 9-chloro-9-[4-(diethylamino)
phenyl]-9,10-dihydro-10-phenylacridine hydrochloride (C-390). DP swabs were inoculated directly onto
BCSA (Remel, Lenexa, KS) and then RGM medium. Sputum samples and tracheal aspirates were plated
onto BCSA and then RGM medium by using a sterile swab. A 100-l aliquot of undiluted BW and BAL
fluids was used for inoculation. Sputolysin (EMD Millipore, Billerica, MA) was added dropwise as needed
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to homogenize viscous BW/BAL fluid. A 100-l aliquot of the Sputolysin-sample mixture was inoculated
onto the two media after being vortexed and left at room temperature for 15 min. No treatment with
Sputolysin was performed on sputum and tracheal aspirates. BCSA was initially incubated at 35°C in air
for 4 days as part of the routine CF culture protocol and was then incubated at 30°C for 24 days. RGM
medium was incubated at 30°C in air for 28 days. Both media were examined at 4, 7, 10, 14, 21, and 28
days.
Specimen processing and culture method for mycobacteria (AFBC). A subset of samples had
mycobacterial culture performed in addition to culture on BCSA and RGM medium. All CF respiratory
samples underwent double decontamination with NALC–2% NaOH and oxalic acid before inoculation
into an MGIT (Becton Dickinson, Sparks, MD) and LJ medium (Remel). Briefly, up to 5 ml of sputum/
tracheal aspirate samples or concentrated BW/BAL fluid (centrifuged at 2,500 rpm for 15 min) was treated
with an equal amount of the BBL MycoPrep reagent (NALC-NaOH; Becton Dickinson), vortexed, and
incubated at room temperature for 15 min. BBL MycoPrep phosphate buffer (PB; Becton Dickinson) was
added to give a final volume of 50 ml, and this mixture was centrifuged at 3,900 rpm for 15 min. The
supernatant was discarded, and the sediment was resuspended in 2 ml of sterile PB. An equal amount
(approximately 2 ml) of 5% oxalic acid (Remel) was added to make a final concentration of 2.5% oxalic
acid after a smear for Truant auramine-rhodamine stain was prepared. The specimen was incubated at
room temperature for 30 min, with vortexing at 10-min intervals. The steps of adding PB and centrifu-
gation were repeated to obtain 2 ml of treated sample, and this sample was then adjusted to an optimal
pH of between 6.9 and 7.2 by using 4% NaOH or 1 N HCl as required. A 0.5-ml aliquot of the processed
specimen was inoculated into an MGIT containing OADC growth supplement (Becton Dickinson) and
PANTA (polymyxin B-amphotericin B-nalidixic acid-trimethoprim-azlocillin) antimicrobial supple-
ment (Becton Dickinson), prepared according to the manufacturer’s protocol. The inoculated MGIT
was loaded onto a Bactec MGIT 960 instrument (Becton Dickinson) and incubated at 37°C, with
continuous monitoring of growth for 42 days. A solid medium (LJ medium) was also inoculated with
4 drops of the processed specimen. LJ medium was examined after 4, 7, 10, and 14 days and then
weekly for up to 56 days.
Identification of mycobacteria and other microorganisms. A Kinyoun stain was prepared from any
colonies consistent with mycobacteria growing on BCSA, RGM medium, and LJ medium and from broth
from any positive MGIT. AFB-positive colonies and AFB-positive MGIT samples were subcultured on
Middlebrook 7H11 agar (Remel) and incubated at 30°C in air for subsequent identification. Any AFB-
negative bacterial colonies recovered on BCSA and RGM medium were subcultured on Trypticase soy
agar with 5% sheep blood (Becton Dickinson) and were further identified by using the MALDI-TOF MS
(Vitek MS, bioMérieux, Durham, NC) IVD system with the Knowledge Base version 2.0 database after 24
h of incubation at 35°C in 5% CO2. Candida spp. and Trichosporon spp. were presumptively identified by
colony and Gram stain morphologies. There was no further identification of molds or Kinyoun-negative
organisms from positive MGIT and LJ medium cultures. The Vitek MS research-use-only (RUO) system
with the SARAMIS v4.12 database (bioMérieux) was used to identify mycobacteria that were subcultured
on Middlebrook 7H11 agar after 72 to 96 h of incubation according to the manufacturer’s recommen-
dations (18). Confidence scores of 75% were acceptable for species identification according to our
previous validation study and our laboratory protocol. Slowly growing mycobacteria and bacteria that
could not be identified by MALDI-TOF MS were identified by using partial sequencing of the 16S rRNA
gene as previously described (19).
Evaluation of MALDI-TOF MS for identification of rapidly growing mycobacteria on BCSA and
RGM medium. Forty-one archived isolates were used to evaluate the performance of MALDI-TOF MS for
the identification of rapidly growing mycobacteria on BCSA and RGM medium. The isolates included
Mycobacterium abscessus subsp. abscessus (n  11), M. abscessus subsp. massiliense (n  11), M. chelonae
(n  5), the M. fortuitum complex (n  6), M. mucogenicum (n  5), and M. immunogenum (n  3). The
species of all strains were previously identified by MALDI-TOF MS from colonies grown on Middlebrook
7H11 agar using the method described above (18). The subspecies of M. abscessus was identified by
whole-genome sequencing at the Wellcome Trust Sanger Institute (Hinxton, UK) as described previously
(20). The isolates were stored at 80°C in Middlebrook 7H9 broth with glycerol (Becton Dickinson). A
10-l aliquot of frozen isolates was subcultured on Trypticase soy agar with 5% sheep blood (Becton
Dickinson) and incubated at 30°C in air. The isolates were then subcultured on BCSA and RGM medium
and incubated at 30°C in air. MALDI-TOF MS was performed on the isolates after 72 to 96 h of incubation
depending on the growth rate in accordance with the methods described above by using the Vitek MS
RUO system with the SARAMIS database. Additional spectrum analysis was performed by using the new
v3.0 Knowledge Base database for the Vitek MS system (bioMérieux).
Statistical analysis. The differences in the performances of the culture methods were analyzed by
using McNemar’s test with the continuity correction applied. Statistical significance was taken as a
P value of 0.05.
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